glp-1 and alcohol consumption A preliminary study of the physiological perceptual effects of receptor agonists during in people with obesity GLP-1s Hold Promise as Treatment

Sulfasalazine, a potent suppressor of lymphoma growth by inhibition of the x(c)-cystine transporter: a new action for an old drug

Tabassum R, Imtiaz F, Sharafat S, Shukar-Ud-Din S, Nusrat U

Characterization of Brainstem Preproglucagon Projections to the Paraventricular and Dorsomedial Hypothalamic Nuclei

Alio del Barrio, J

CMS Issues Coverage Guidance on GLP-1 Anti-Obesity Drugs: Implications for Health Plans Posted on April 5, 2024 CMS Issued Coverage Guidance on GLP-1 Anti-Obesity Drugs Requiring Considerations for Health Plans GLP-1s (glucagon-like peptide 1 agonist) came up in the news again after the Centers for Medicare and Medicaid Services (CMS) issued coverage guidance on GLP-1 anti-obesity drugs with expanded indications on March 20, 2024.* Since the inception of Medicare Part D, drugs used for weight loss have been excluded from basic coverage